International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2026
A Novel BORCS5 Loss-Of-Function Variant in a Patient With a Rare Neurodevelopmental Disorder.
СтатьяКлинический случайНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mahmood Arif, Shah Abid Ali, Zaman Gohar, Masroof Shazra, Waqas Ahmed, Umair Muhammad
Аннотация
BACKGROUND: The BORCS5 is an important and critical component of the BLOC-one-related complex (BORC), involved in kinesin-dependent anterograde lysosomal transport. Aberrations in the octameric protein complex encompass lethal neurological manifestations, such as arthrogryposis multiplex congenita, brain malformations and neuropathological evidence of diffuse neuroaxonal dystrophy. Loss-of-function variants in BORCS5 are associated with extremely rapid and progressive neurodegeneration.
METHODS: Herein, we present a family consisting of a proband with intellectual disability, microcephaly, developmental delay, facial dysmorphism, dystonia, focal/generalized seizures and speech delay. We performed whole-exome sequencing followed by Sanger sequencing for molecular diagnosis. Further, we performed 3D protein modelling for structural interpretation.
RESULTS: Genetic analysis identified a novel stop-gain variant (NM_058169.6, c.262C>T; NP_477517.1, p.(Gln88*)) in BORCS5, subsequently confirmed by Sanger sequencing. The variant is likely pathogenic (PVS1, PM2, PP3). Protein modelling of the BORCS5; p.(Gln88*) variant showed a distinct conformation compared with the wild-type BORCS5, suggesting a potential role for the unfolded protein response in the pathogenesis of BORCS5.
CONCLUSION: In summary, our findings exemplify a novel stop-gain variant in BORCS5 associated with diverse pathological manifestations, underscoring the importance of further exploring this gene in patients lacking identifiable disease-causing gene variants.
METHODS: Herein, we present a family consisting of a proband with intellectual disability, microcephaly, developmental delay, facial dysmorphism, dystonia, focal/generalized seizures and speech delay. We performed whole-exome sequencing followed by Sanger sequencing for molecular diagnosis. Further, we performed 3D protein modelling for structural interpretation.
RESULTS: Genetic analysis identified a novel stop-gain variant (NM_058169.6, c.262C>T; NP_477517.1, p.(Gln88*)) in BORCS5, subsequently confirmed by Sanger sequencing. The variant is likely pathogenic (PVS1, PM2, PP3). Protein modelling of the BORCS5; p.(Gln88*) variant showed a distinct conformation compared with the wild-type BORCS5, suggesting a potential role for the unfolded protein response in the pathogenesis of BORCS5.
CONCLUSION: In summary, our findings exemplify a novel stop-gain variant in BORCS5 associated with diverse pathological manifestations, underscoring the importance of further exploring this gene in patients lacking identifiable disease-causing gene variants.